ArticleBasic and clinical andrology2025
Seminal 5'tRF-Glu-CTC as a Biomarker for Oligozoospermia and ART Outcome Prediction.
Article in Basic and clinical andrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Comparative Analysis of Reported Gene Targets and Binding Regions of Glu-CTC tRNA Fragments Across Human Diseases.Biomolecules · 2026Article
- Non-Coding RNA Biomarkers in Male Infertility: From Discovery to Clinical Actionability-A Narrative Review.Genes · 2026Review
- The bull sperm epigenome: role in male fertility and transmission to the offspring.The Journal of reproduction and development · 2026Review
- Advances in the diagnosis and treatment of oligoasthenozoospermia based on epigenetic regulation.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEpigenetic mechanisms influencing sperm production and function are closely linked to male infertility. Among these, tRNA-derived fragments have recently been identified as important modulators of cellular stress responses and gene expression. The purpose of this study was evaluate the potential role of 5'tRF-Glu-CTC in the context of assisted reproductive technologies (ART) outcomes by comparing its differential expression in the seminal plasma of oligozoospermic and normozoospermic infertile men.
resultsTotal RNA was extracted from seminal plasma, and 5'tRF-Glu-CTC expression was measured by qRT-PCR. Sperm DNA fragmentation index (DFI) was assessed via the TUNEL assay. The results revealed significantly elevated 5'tRF-Glu-CTC expression in the oligozoospermic group compared to the normozoospermic group (15.58 ± 4.34 vs. 12.53 ± 4.99; fold change: 1.692; P = 0.024). Sperm DFI showed a significant negative correlation with both the progressive motile sperm (ρ = -0.537, P = 0.015) and the total progressive motile sperm count (ρ = -0.509, P = 0.026). However no significant differences in DFI was observed between the oligozoospermic and control groups (P > 0.05). Analysis of ART outcomes revealed that male partners of couples who achieved pregnancy had lower mean 5'tRF-Glu-CTC expression and DFI, although these differences did not reach statistical significance (P > 0.05).
conclusionsThese results suggest that 5'tRF-Glu-CTC might be serve as a potential biomarker and could play a role in the pathophysiology of oligozoospermia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.